Travere Therapeutics (TVTX) Price & Analysis

Compare

509 Followers

TVTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.83 - $25.29

Previous CloseN/A

Volume140.04K

Average Volume (3M)1.46M

Market Cap

$1.55B

Enterprise Value$1.40B

Total Cash (Recent Filing)$319.54M

Total Debt (Recent Filing)$399.57M

Price to Earnings (P/E)―

Beta1.57

Next Earnings

Nov 05, 2025

EPS Estimate

-0.27

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding89,138,670

10 Day Avg. Volume1,536,673

30 Day Avg. Volume1,462,090

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.90

Enterprise Value/Revenue4.18

Enterprise Value/Gross Profit4.51

Enterprise Value/Ebitda-11.21

Forecast

1Y Price Target

$34.17

Price Target Upside95.93% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

EarningsFilspari reported strong results with a total revenue of $114M, exceeding consensus expectations of $100M.

Market PositionTravere noted that the dual mechanism of Filspari is differentiated relative to competition, enhancing its market position.

Regulatory ApprovalTravere's lead asset, Filspari/sparsentan, received FDA full approval for the treatment of IgA nephropathy, which enhances the company's growth prospects.

Bears Say

Market ExpectationsFilspari metrics, despite showing growth, mildly disappointed investors.

Travere Therapeutics News

Nvidia reports Q2 beat, Snowflake posts ‘beat and raise’: Morning Buzz

The major averages were mixed near noon, with the Dow fractionally in the red, following Nvidia’s earnings report....

6h ago

Ligand price target raised to $206 from $157 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Ligand (LGND) to $206 from $157 and keeps a Buy...

8h ago

LGND

TVTX

Travere Therapeutics price target raised to $47 from $30 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $30 and keeps a...

12h ago

TVTX

Travere Therapeutics’ filspari granted FDA approval for REMS labeling

Travere Therapeutics (TVTX) announced that the FDA has approved updated Risk Evaluation and Mitigation Strategy, or REMS, labeling...

1d ago

TVTX

Travere Therapeutics price target raised to $34 from $32 at Citi

Citi raised the firm’s price target on Travere Therapeutics (TVTX) to $34 from $32 and keeps a Buy...

18d ago

TVTX

Travere Therapeutics price target raised to $31 from $30 at Scotiabank

Scotiabank raised the firm’s price target on Travere Therapeutics (TVTX) to $31 from $30 and keeps an Outperform...

21d ago

TVTX

Travere Therapeutics price target raised to $32 from $30 at Wedbush

Wedbush raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $30 and keeps an Outperform...

21d ago

TVTX

Travere Therapeutics reports Q2 EPS (14c), consensus (1c)

Reports Q2 revenue $114.4M, consensus $100.2M. “We continue to make strong progress against our strategic priorities, putting Travere...

22d ago

TVTX

Buy Rating Affirmed for Travere Therapeutics Amid Positive FDA Changes for Filspari

In a report released yesterday, Jason Zemansky from Bank of America Securities maintained a Buy rating on Travere...

12h ago

TVTX

Strategic Positioning and Growth Potential Drive Buy Rating for Travere Therapeutics

Yigal Nochomovitz, an analyst from Citi, maintained the Buy rating on Travere Therapeutics. The associated price target remains...

10d ago

TVTX

Positive Growth Outlook for Travere Therapeutics Driven by Filspari’s Market Potential and Strategic Initiatives

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on TVTX stock, giving a Buy rating on...

18d ago

TVTX

Strong Sales Performance and Market Expansion Potential Drive Buy Rating for Travere Therapeutics

Joseph Schwartz, an analyst from Leerink Partners, maintained the Buy rating on Travere Therapeutics. The associated price target...

21d ago

TVTX

Travere Therapeutics Earnings Call Highlights FILSPARI Success

Travere Therapeutics, Inc. (($TVTX)) has held its Q2 earnings call. Read on for the main highlights of the...

21d ago

TVTX

Travere Therapeutics Reports Strong Q2 2025 Growth

Travere Therapeutics, Inc. ( ($TVTX) ) has released its Q2 earnings. Here is a breakdown of the information...

22d ago

TVTX

TVTX FAQ

What was Travere Therapeutics, Inc.’s price range in the past 12 months?

Travere Therapeutics, Inc. lowest stock price was $8.83 and its highest was $25.29 in the past 12 months.

What is Travere Therapeutics, Inc.’s market cap?

Travere Therapeutics, Inc.’s market cap is $1.55B.

When is Travere Therapeutics, Inc.’s upcoming earnings report date?

Travere Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 69 days.

How were Travere Therapeutics, Inc.’s earnings last quarter?

Travere Therapeutics, Inc. released its earnings results on Aug 06, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.312 by $0.172.

Is Travere Therapeutics, Inc. overvalued?

According to Wall Street analysts Travere Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Travere Therapeutics, Inc. pay dividends?

Travere Therapeutics, Inc. does not currently pay dividends.

What is Travere Therapeutics, Inc.’s EPS estimate?

Travere Therapeutics, Inc.’s EPS estimate is -0.27.

How many shares outstanding does Travere Therapeutics, Inc. have?

Travere Therapeutics, Inc. has 89,138,670 shares outstanding.

What happened to Travere Therapeutics, Inc.’s price movement after its last earnings report?

Travere Therapeutics, Inc. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.312. Following the earnings report the stock price went down -1.914%.

Which hedge fund is a major shareholder of Travere Therapeutics, Inc.?

Currently, no hedge funds are holding shares in TVTX

Travere Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-705.73%

Trailing 12-Months

Asset Growth

0.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Travere Therapeutics, Inc.

Travere Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of innovative therapies for rare diseases. The company specializes in addressing unmet medical needs for patients with conditions such as kidney diseases and metabolic disorders. Travere's core products include approved therapeutics such as Filspari (sparsentan) and its pipeline candidates aimed at treating various rare diseases, leveraging its expertise in drug development and clinical research.

Travere Therapeutics (TVTX) Earnings & Revenues

Historic Earnings Reports

TVTX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong financial and commercial performance, particularly for FILSPARI in IgA nephropathy, and positive clinical data supporting its efficacy. Strategic advancements in expanding FILSPARI's indications and robust pipeline development were emphasized. However, increased SG&A expenses and potential generic competition for THIOLA products were noted as challenges. Overall, the positive developments surpassed the lowlights.View all TVTX earnings summaries

TVTX Stock 12 Month Forecast

Average Price Target

$34.17

▲(95.93% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","18":"$18","28":"$28","38":"$38","48":"$48"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$47.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,18,28,38,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.63,18.043076923076924,20.456153846153846,22.869230769230768,25.28230769230769,27.69538461538461,30.108461538461537,32.52153846153846,34.934615384615384,37.347692307692306,39.76076923076923,42.17384615384615,44.58692307692307,{"y":47,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.63,17.056153846153848,18.482307692307693,19.908461538461538,21.334615384615386,22.76076923076923,24.18692307692308,25.613076923076925,27.03923076923077,28.465384615384615,29.89153846153846,31.317692307692308,32.74384615384616,{"y":34.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.63,15.966153846153848,16.302307692307693,16.638461538461538,16.974615384615387,17.310769230769232,17.646923076923077,17.983076923076922,18.31923076923077,18.655384615384616,18.99153846153846,19.327692307692306,19.663846153846155,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.24,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.47,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.99,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.57,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.42,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.44,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.76,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.52,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >